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Abstract Pharmacological treatment of pain in multiple
sclerosis (MS) is challenging due to the many underlying
pathophysiological mechanisms. Few controlled trials show
adequate pain control in this population. Emerging evi-
dence suggests that pain might be more effectively classi-
fied and treated according to symptoms and underlying
mechanisms. The new mechanism-based classification we
propose here distinguishes nine types of MS-related pain:
trigeminal neuralgia and Lhermitte’s phenomenon (parox-
ysmal neuropathic pain due to ectopic impulse generation
along primary afferents), ongoing extremity pain (deaffer-
entation pain secondary to lesion in the spino-thalamo-
cortical pathways), painful tonic spasms and spasticity pain
(mixed pains secondary to lesions in the central motor
pathways but mediated by muscle nociceptors), pain asso-
ciated with optic neuritis (nerve trunk pain originating from
nervi nervorum), musculoskeletal pains (nociceptive pain
arising from postural abnormalities secondary to motor
disorders), migraine (nociceptive pain favored by predis-
posing factors or secondary to midbrain lesions), and
treatment-induced pains. Identification of various types of
MS-related pain will allow appropriate targeted pharma-
cological treatment and improve clinical practice.
Keywords Multiple sclerosis  Pain prevalence 
Treatment trial  Neuropathic pain  Spasticity  Migraine
Introduction
Research into pain and pain management has long debated
the relationship symptom-mechanism-treatment. Newly
proposed screening questionnaires, and diagnostic proce-
dures such as quantitative sensory testing, pain-related
evoked potentials, and skin biopsy [19, 33], have advanced
the mechanistic approach to pain management leading to the
development of the so-called sensory profiles [6, 9, 20, 59].
Making a specific diagnosis, understanding the under-
lying pathophysiological mechanism and implementing the
proper treatment strategy depends first of all on clearly
defining the various types of pain.
In this partly systematic but largely argumentative
review, we sought epidemiological and pharmacological
studies on MS-related pain. Seeking support for our pro-
posed mechanism-based classification for MS-related pain,
we then reviewed studies that help to define and understand
the various types of MS-related pain. From current
knowledge, our own clinical experience, and information
gained from our review, we then tried to classify the dif-
ferent types of MS-related pain according to the underlying
pathophysiological mechanism.
We distinguish five pain categories, nociceptive, neu-
ropathic, psychogenic, idiopathic, and mixed. These cate-
gories are variably established in the literature. A PubMed
search including papers published from inception date to
2011 showed how many articles used these terms:
• neuropathic pain: 7,759,
• nociceptive pain (378) or inflammatory pain (1,868);
total: 2,246,
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• psychogenic pain (171) or somatoform pain (136) or
pain behavior (244); total: 551,
• idiopathic pain: 74,
• mixed pain: 46.
To sharpen the distinction between nociceptive pain
(whether inflammatory or non-inflammatory), namely pain
resulting from nociceptor activation by true or potentially
tissue-damaging stimuli, and neuropathic pain, the Inter-
national Association for the Study of Pain (IASP) has
redefined neuropathic pain as pain arising directly from a
lesion or disease affecting the somatosensory system [105].
The previous definition (pain initiated or caused by a pri-
mary nervous system lesion or dysfunction) left room for
numerous conditions that are neither really or wholly
neuropathic. For example, the word dysfunction allowed
inclusion of pain related to secondary functional and neu-
roplastic changes in the nervous system resulting from
sufficiently strong nociceptive stimulation, e.g., central
sensitization [14, 106]. The phrasing initiated by a primary
lesion in the nervous system left room for any pain in
neurological disease, in particular all musculoskeletal pains
secondary to movement disorders [26, 73, 91], a major
problem in patients with MS.
Among the five categories of pain, one that is difficult to
define is psychogenic pain. This term refers to both primary
psychiatric conditions such us somatoform pains associated
with anxiety and depression [30, 36, 47, 53, 84], and also to
the superimposed psychogenic components that often
develop in patients with chronic refractory pain. This
possibility is important to remember because patients with
chronic pain may develop a psychogenic component that
overwhelms the original organic disease and lose compli-
ance to the theoretically correct therapy (a condition also
called pain behavior) [99, 108].
The category idiopathic pain encompasses several
poorly understood or controversially interpreted chronic
pain conditions, including fibromyalgia, irritable bowel
syndrome, interstitial cystitis, and persistent idiopathic
facial pain [24, 93], all of which may share a common
genetic predisposition or be related to some kind of brain
dysfunction [51, 67, 96]. Because countless patients
experience idiopathic pain, the field attracts major research
efforts.
The term mixed pain is the least used and the concept
remains controversial [8, 87]. Indeed, many pain clinicians
and investigators deny its usefulness, arguing that the term
‘‘mixed’’ adds nothing to ‘‘coexisting’’. Because many
patients may experience more than one type of pain and
may have two or more diseases, we need to clarify the
difference between ‘‘coexisting’’ and ‘‘mixed’’.
Coexisting pains are unrelated: their causes and patho-
physiological mechanisms differ and they require
independent treatment. For instance, in a patient with
syringomyelia involving the C5 dermatome who also has a
periarthritis shoulder, two independent conditions that just
happen to share a similar territory exist and must be
independently managed. A more intriguing example comes
from a patient with trigeminal neuralgia affecting the
mandibular division who has a coexisting temporoman-
dibular disorder. This patient may report the typical electric
shock-like attacks of trigeminal neuralgia and a dull, deep,
and ongoing pain in the same territory and must therefore
be distinguished from a patient with atypical trigeminal
neuralgia, a neuropathic pain that entails both paroxysmal
and background pain [70]. Neither patient has mixed pain.
Conversely, in mixed pain, the same disease causes
different pains through different pathophysiological
mechanisms that are often difficult to separate and quantify
and may therefore raise management problems. A frequent
condition that fits this definition is low back pain with
sciatica, including both nociceptive components arising
from muscles, ligaments, and joints, and neuropathic
component arising from the spinal root. When the involved
spinal roots innervate proximal territories the neuropathic
and nociceptive components may be difficult to separate.
Besides spinal root compression, inflammatory mediators
originating from the degenerative disc may induce radic-
ular pain without any mechanical compression or noci-
ceptive sprouts within the degenerated disc may give rise to
local neuropathic pain [27]. An important example of
mixed pain comes from cancer pain. When lung cancer
invades the brachial plexus and the patient feels pain pro-
jected to the hand, neuropathic pain clearly adds to noci-
ceptive pain. Emerging evidence, however, suggests that
cancer is bound to produce mixed pain with a less obvious
mechanism and less clear symptoms: the tumor invading
the surrounding tissues destroys the local nerve endings
thus inducing regenerating sprouts that are rich in a variety
of pain-related channels and also induce central sensitiza-
tion; so far, this has been well established for bone cancer
[49, 62, 76, 117]. In this case, it is impossible to distinguish
between and quantify the nociceptive and neuropathic
components.
For multiple sclerosis, the concept of mixed pain is
especially important because two types of MS-related pain
should be considered mixed: tonic painful spasms and
spasticity pain (see below).
Pain in multiple sclerosis: inadequacy
of epidemiological studies
Pain is a major burden for patients with MS [4, 71, 81]. The
estimated prevalence of MS-related pain ranges widely
from 26 to 86 % [69, 71]. The high variability reflects
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differences in the criteria used to define the various types of
MS-related pain, the types of pain assessed in the epide-
miological survey, the study sample (e.g., population
cohorts, hospitalized patients), and the research methods
(mail surveys, administrative database queries, and in-
person history and examination) [71]. In a systematic
review of pain related to MS, O’Connor and colleagues
[71] found that most studies reported a prevalence higher
than 50 %. In a meta-analysis (restricted to studies that
provided sufficient information and sufficient quality of
methodology), they calculated that 633/854 (74 %) out-
patients had pain within 1 month [71].
The discrepancy in study design and methods accounts
also for differences in the reported risk factors for the
development of pain related to MS (patient’s age, duration
of disease, disease course, and disability). Whereas some
studies reported an association between one or more of
these factors and pain [34, 97], others did not [10, 44, 73].
A large sample study on the prevalence of pain in MS [97]
identified as the main factors associated with the devel-
opment of pain a longer duration of disease, older age, a
non-relapsing-remitting MS course and greater disability.
A possible drawback of this finding is that all these factors
are intermingled and the study lacked a multivariate anal-
ysis to distinguish the role of single factors. The role of the
various risk factors in the development of pain therefore
awaits clearer answers.
Pain in multiple sclerosis: insufficiency
of pharmacological trials
A search of the electronic literature from date of inception
to April 2012 showed that only 12 randomized placebo-
controlled trials (RCTs) have assessed pharmacological—
non disease-modifying—treatment of pain in MS (see
‘‘Appendix’’ for details about this search). For comparison
with MS, we chose diabetic painful neuropathy, because
the prevalence of pain in diabetes has been reliably
assessed (most studies agree on values between 16 and
19 %) [22, 23] and is far lower than the estimated preva-
lence of pain in MS (74 %). Nevertheless, when we sur-
veyed the literature, we found 188 RCTs assessing pain in
diabetic neuropathy but only 12 assessing pain in MS.
Articles on diabetes are arguably far more numerous than
those on MS and drug companies tend to prefer a huge
market such as that provided by diabetes. Another reason,
however, for the dearth of drug trials is that until a few
years ago, most physicians tended to underestimate the
importance of pain in MS [71, 103, 107]. Indeed, when we
compared RCTs investigating spasticity and pain in MS,
we found that a considerably larger number assessed
spasticity than pain (33 vs. 12) and several of the latter
were RCTs targeting spasticity that also included pain
relief as one of the outcome variables (Table 1).
Besides the scarcity of RCTs assessing pain related to
MS, our review identified other problems. Of the 12 RCTs
reviewed, we found only four dedicated to pain assessment
[13, 86, 88], whereas all the others included some pain
measure as an item in quality-of-life scales or spasticity
scales, and even more importantly, five studies failed to
describe the type of pain [15, 54, 75, 94, 113], and only one
generically mentioned ‘‘central pain’’, without specifying
further or distinguishing paroxysmal pain (such as tri-
geminal neuralgia) from ongoing pain (such as extremity
pain) [13]. Of these six trials, only one, testing dex-
tromethorphan/quinidine, was unambiguously successful in
relieving pain [75].
One study investigated ongoing extremity pain [88], one
ongoing extremity pain and a few patients with painful
tonic spasms [86], one central pain, but specifying that
most patients had extremity pain [100], and three others
assessed pain related to spasticity and spasms [21, 39, 116].
Of these six trials, only one, using botulinum toxin injec-
tions, was unsuccessful in relieving pain [39]. Although the
success of a trial depends strongly on the active treatment,
among all the trials testing cannabinoids, the only one
reporting no significant pain relief was the one that failed to
take into account the type of pain [113]. Our finding that
the frequency of success differs significantly (p = 0.02;
Chi-square) between studies that adequately categorized
the type of pain and those that did not (Table 1) confirms
that pain mechanisms do differ and pharmacological trials
should aim to target specific types of pain.
Finally, whereas many trials assessed cannabis deri-
vates, no RCT exists on the drugs that have for long been
most popular in treating neuropathic pain (amitriptyline
and carbamazepine) or are currently popular (pregabalin
and serotonin noradrenaline reuptake inhibitors) [7, 102].
Proposed classification for pain in multiple sclerosis
In 2008, O’Connor and colleagues [71] published a useful
review that also proposed a classification for pain in mul-
tiple sclerosis, as we are doing. With respect to theirs, our
classification is more based on pathophysiological mecha-
nisms and response to treatment, and most notably differs
in our introduction of the mixed pain category.
Neuropathic pains
Considering the two most reliable studies that assessed the
prevalence of neuropathic pain through clinical examina-
tion, 129/414 patients (31 %) had one or more types of
neuropathic pain [73, 101] (Table 2).
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Ongoing extremity pain
Although most published studies on MS describe this type
of pain as dysesthetic extremity pain, this terminology
contrasts with the definition of sensory disturbances pro-
posed by the IASP and generally accepted in pain research:
dysesthesia indicates an ‘‘unpleasant abnormal sensation,
whether spontaneous or evoked’’ [40]. To avoid confusion,
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Blue cells highlight studies that specified the type of pain and had an unambiguously positive outcome on pain. Red cells highlight studies that
did not specify the type of pain and did not have an unambiguously positive outcome on pain. Note that the accuracy in specifying the type of
pain and outcome was uncoupled in only two of 12 trials [39, 75]
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we therefore recommend defining this condition, charac-
terized by constant (and often burning) pain that predom-
inantly affects legs and feet, as ongoing extremity pain
[107]. The reported lifetime prevalence rates range
between 12 and 28 % [69, 71]. This type of pain is more
common in patients with the primary progressive or the
progressive-relapsing types of MS, and lowest in the
relapsing–remitting type [11, 69]. Patients with this type of
pain tend on average to be more disabled than those
without pain [69].
The pathophysiology of ongoing extremity pain is
poorly understood. Magnetic resonance imaging studies
usually show plaques in the cervical and thoracic spinal
cord. Hence, this type of pain may arise from lesions in the
spinal cord nociceptive pathways. This pathophysiological
view receives support from clinical studies in patients with
this type of pain showing that thermal-pain sensitivity,
sensitivity mediated by the spinothalamic system, is more
likely to be affected than lemniscal sensitivities [74]. The
bilateral and relatively distal distribution is more difficult
to explain. Ample evidence (including studies using elec-
troneurography and skin biopsy) excludes peripheral nerve
involvement [73, 78]. Patients with this type of pain pre-
sumably have bilateral central lesions, probably multiple
Table 2 Proposed classification of pain in multiple sclerosis
Types of pain
(% frequency)
Possible mechanisms Theoretical treatment
Neuropathic pains
1. Ongoing extremity pain
(12–28 %)
Thalamic or cortical deafferentation pain by multiple lesions





High-frequency discharges ectopically generated by intra-axial
inflammatory demyelination plus extra-axial mechanical





High-frequency discharges ectopically generated by
demyelination of the dorsal column primary afferents
Sodium-channel blockers
Mixed pains
1. Painful tonic spasms
(6-11 %)
High-frequency discharges ectopically generated by
demyelination in the corticospinal pathways induce spasmodic
muscle contractions, which in turn induce ischemic muscle pain
Sodium-channel blockers
Cannabinoids
2. Spasticity pain (\50 %) Disinhibition by a corticospinal tract lesion enhances the tonic
stretch reflex, which in turn gives rise to excessive muscular




1. Nerve trunk pain associated
with optic neuritis (8 %)






Postural anomalies secondary to motor disturbances Standard pharmacological treatment and
physiotherapy for mechanical
musculoskeletal pain
2b. Back pain (10–16 %) No evidence has yet excluded the possibility that in addition to
the aforementioned postural anomalies MS may itself directly
contribute to back pain
Standard pharmacological treatment and
physiotherapy for back pain
3a. Migraine (34 %) The two diseases share predisposing factors
Midbrain lesions
Standard treatment for migraine
3b. Tension-type headache
(21 %)
No evidence against two chance coexisting conditions Standard treatment for tension headache
4. Treatment-induced pains (?) See text
Other pains See text
The % frequencies calculated in the first column take into account the total number of MS patients. Because many patients may have two or more
types of pain, the sum of these % frequencies exceeds 100. The most reliable estimate for total pain prevalence in MS is 74 %
\50 %: Because pain is frequently though not invariably manifested by patients with spasticity its prevalence must be lower than that of
spasticity, which is about 50 %
(?): we have no direct estimate; the estimates of other types of pain cannot be simply subtracted from estimates of pain in general because many
patients have more than one type of pain
In the third column, cannabinoids are always in second row because their mechanism is less specific (not because second-line treatment)
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lesions, predominantly affecting the feet and legs because
the relevant spinothalamic fibres run a longer course and
are somatotopically located closer to the spinal cord sur-
face. Fiber length and a location closer to the cerebrospinal
fluid (CSF) [64] both increase the probability of demye-
linating processes developing (Fig. 1). Brain white matter
lesions might also contribute, because most of them are
periventricular [64]. Heading for the primary somatosen-
sory area, the thalamocortical fibers for the face diverge
laterally, whereas those for the foot ascend close to the
lateral ventricle (Fig. 1). Although the opercular-insular
cortical areas undoubtedly intervene in pain processing,
ample evidence now shows that also in humans the primary
somatosensory area plays an important role [42, 46, 83]. In
brief, the distal and bilateral distribution of this kind of
MS-specific pain probably depends on the length of the
spinal thalamocortical system dedicated to the lower
extremity and on its somatotopic location in the spinal cord
and brain.
Trigeminal neuralgia
Trigeminal neuralgia (TN) consists of paroxysmal attacks
of electric-shock-like sensations that may develop sponta-
neously or be evoked by innocuous stimuli in specific
facial or intraoral areas (trigger zones). By definition,
typical TN is a pain syndrome that arises without a clini-
cally manifest sensory deficit. TN is termed classic when
investigation identifies no cause other than a neurovascular
contact or symptomatic when secondary to major neuro-
logical disease [17, 31, 35]. Symptomatic TN is frequently
related to MS, patients with MS having a 20-fold increased
risk of trigeminal neuralgia [48]. About 2–5 % of patients
with MS have typical TN [38, 43, 48, 73, 97, 101].
Multiple sclerosis-related TN has for long been attrib-
uted to a demyelinating plaque in the pons, as postmortem
specimens indicate [43, 55]. The plaque theory neverthe-
less contrasts with the frequent neuroimaging finding of a
neurovascular contact with the trigeminal root in patients
with TN and MS and the existence of some patients with
MS who have TN as the sole clinical manifestation; others
therefore proposed that in most patients with MS, TN
merely reflects the high frequency of neurovascular con-
tacts in the normal population [5, 12, 25]. Indeed, histo-
pathological studies of surgical specimens describe
demyelination in the proximal, centrally myelinated part of
the trigeminal root in patients with MS-related TN and in
those with classic TN [56, 57]. A clear-cut difference,
however, is that trigeminal reflex testing is abnormal in
89 % patients with MS-related TN, but in only 3 % of
patients with classic TN [17, 31].
A recent neuroimaging-neurophysiological study in 130
patients with MS, 50 having typical TN, confirmed that in
most patients TN was caused by a demyelinating plaque
along the intra-axial primary afferents [16]. Other findings
in that study nevertheless showed that the TN-group
Fig. 1 Somatotopy of the spinothalamocortical system. Schematic
drawing of a coronal section of the brain (above) and an axial section
of the spinal cord at cervical level (below). In the brain, F, H, and L
refer to face, hand, and leg. In the spinal cord C, T, L, and S refer to
cervical, thoracic, lumbar, and sacral. In the spinal cord, unlike the
dorsal columns and similarly to the corticospinal tract, the spinotha-
lamic tract keeps the fibres for the lower limb (L and S) more
superficial. In more caudal sections, the arrangement is identical to that
of the corticospinal tract, i.e., in layers with sacral fibers external and
cervical fibers internal. At the cervical level, the spinothalamic fibers
tend progressively to assume the medial (cervical)–lateral (sacral)
arrangement that will be maintained throughout the brainstem, where
the additional trigeminothalamic fibers join the ascending tract
medially. In the ventrobasal complex of the thalamus, the arrangement
is still medial–lateral with neurons for the face medial and those for the
leg lateral, but the sensory homunculus has the opposite somatotopic
organization, thus the thalamocortical fibers for the face must diverge
laterally, whereas those for the leg ascend vertically, traveling close to
the lateral ventricle. In the spinal cord, brainstem, and brain, the
spinothalamic fibers for the leg travel close to the CSF
356 J Neurol (2013) 260:351–367
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differed from the other patients with MS, both those with
trigeminal symptoms other than TN and those with no
trigeminal involvement. Only the patients with TN showed
the right-left asymmetry typically seen in classic TN and
had symptom onset at an older age than MS patients
without TN and younger age than patients with classic TN,
suggesting that in patients with MS, some other mechanism
contributes to the development of TN, probably a neuro-
vascular contact, acknowledged as the most frequent cause
of classic TN [17, 31, 35]. These two pathogenetic mech-
anisms, MS plaque, and a neurovascular contact, would act
on the same primary axons and both would produce
demyelination [56, 57]. A dual mechanism involving MS
and a neurovascular contact (Fig. 2) receives support from
neurosurgical studies on the outcome of microvascular
decompression because patients with MS-related TN,
despite benefiting less than patients with classic TN,
experienced considerable pain relief [5, 12, 25].
Lhermitte’s phenomenon
Lhermitte’s phenomenon is defined as ‘‘a transient short-
lasting sensation related to neck movement and felt in the
back of the neck, lower back, or in other parts of the body’’
[2, 71]. Although not unique to MS, Lhermitte’s phenom-
enon is frequently associated with MS. In many patients,
this symptom is transient, and manifests only for some
weeks then resolves spontaneously [69]. The reported
prevalence of Lhermitte’s phenomenon varies widely. The
three studies that analyzed Lhermitte’s phenomenon in at
least 100 patients with MS, found it in 313 patients out of
2,085, yielding an overall prevalence of 15 % [2, 45, 97].
Lhermitte’s phenomenon probably depends on a demye-
linating plaque in the dorsal columns at cervical level, as
suggested by two MRI studies that found a strong associ-
ation between Lhermitte’s phenomenon and the presence
of plaque formations in the posterior cervical spine [2, 32].
Given the quality and duration of pain (patients often
describe it as a very short-lasting electric-shock-like sen-
sation), very similar to—though less intense than—the
paroxysms of trigeminal neuralgia, we hypothesize the
same mechanism, i.e., ectopic generation of a high-fre-
quency discharge along the intra-axial portion of first-order
sensory neurons. Were this the responsible mechanism,
patients should benefit from sodium-channel blockers.
Although Lhermitte’s phenomenon is a frequent sensory
disturbance in patients with MS, few patients report this
symptom spontaneously and only few consider it as pain-
ful. Probably for this reason, only one study directly dealt
with treatment of this condition [89]. This controlled study
investigated the effect of intravenously injected lidocaine
and oral mexiletine in 30 patients with paroxysmal
MS-related sensory disturbances (12 patients had
Fig. 2 A dual mechanism for trigeminal neuralgia in MS patients.
Top a voxel-based analysis (see [18] for methods) of the MRI scans in
50 patients with MS and trigeminal neuralgia showed that the area of
maximal probability of lesion (red = p \ 0.0001) is located along the
intrapontine course of the trigeminal primary afferents [16]. The
colored area of high probability of lesion is displayed at its proper
location on the relevant section of a stereotactic atlas to show the
corresponding anatomical structures [92]. Mid T2-weighted MRI
image showing an area of demyelination on the intrapontine course of
trigeminal primary afferents in a patient with trigeminal neuralgia
associated with MS. In this representative patient, MS was disclosed
by the onset of right trigeminal neuralgia at the age of 49 years.
Bottom MRA image showing a cerebellar artery that distorts the right
trigeminal root at its entrance into the pons, in the same subject as
above. Mid and bottom MRI images have been flipped vertically and
horizontally to correspond to the atlas image on top. Although in most
patients with MS and trigeminal neuralgia, MRI shows a plaque in the
area shown in the top panel, in several it does not, whereas it often
discloses (when looked for) a neurovascular contact. MS patients
(regardless of the presence of a plaque on MRI) usually have a typical
trigeminal neuralgia indistinguishable from the classic neuralgia
attributed to neurovascular contact, but several characteristics differ-
entiate them from both MS patients without trigeminal neuralgia and
patients with classic trigeminal neuralgia (see text). We propose that
in many patients two mechanisms contribute to the development of
trigeminal neuralgia in MS: intra-axial inflammatory demyelination
[56] plus extra-axial mechanical demyelination [57] both affecting the
same nerve fibers in the root entry zone (red dots)
J Neurol (2013) 260:351–367 357
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Lhermitte’s phenomenon) and found that lidocaine abol-
ished the paroxysmal symptom in ten out of 12 patients,




This type of pain is specific to MS. Painful tonic spasms are
unilateral or bilateral, stereotyped, involuntary muscle
contractions that last less than 2 min and may manifest
several times a day. These spasms usually continue for
weeks or months and then disappear. They can be triggered
by touch, movement, hyperventilation, or emotions, and
are, though seldom, preceded by a ‘‘somesthesic aura’’ [60,
95, 98]. They may start from the face, arm, or leg, and
spread to the adjacent part of the body. Their prevalence
ranges from 6 to 11 %. Painful tonic spasms are more
common in primary and secondary progressive forms of the
disease and their presence correlates positively with age,
disease duration, and disability [69]. The spasms originate
in the central nervous system from hyperactivity in the
central motor fibers, caused by lesions in the internal
capsule, cerebral peduncle, medulla, or spinal cord [71,
98].
Although no direct evidence exists, the typically spas-
modic muscle contraction suggests ectopically generated
high-frequency discharges. Hence, the ideal drugs would
be frequency-dependent, voltage-gated, sodium-channel
blockers. Accordingly, one controlled trial reported the
efficacy of intravenous lidocaine and oral mexiletine [89].
Because of simultaneous activation of adjacent motor units
as in muscles cramps, the spasmodic muscle contraction
induces extreme vasculature compression, ischemia, and
thus activates the muscle nociceptors sensitive to ischemia,
eventually giving rise to nociceptive pain (ischemic muscle
pain) [63]. As soon as the spasm ends the blood flow
returns to normal and pain quickly recedes. Cannabinoids,
theoretically effective on both neuropathic and nociceptive
components, are indeed efficacious, and are more effica-
cious in painful tonic spasms than the purely neuropathic
pains in patients with MS [7, 86].
Spasticity pain
Spasticity is an increased tonic stretch reflex, related to Ia
presynaptic disinhibition due to corticospinal system
damage. It affects about 50–60 % of patients with MS and
is often painful [71, 103]. Some movements may focally
exacerbate spasticity. These exacerbations, often involving
the thigh adductors, are sometimes called contractures or
painful spasms, thus engendering confusion with the
painful tonic spasms described above. Whereas a clear
distinction—clinical and pathophysiological—between
painful tonic spasms and the focal exacerbations of spas-
ticity is widely accepted, our review found that trials on
spasticity often fail to make the distinction clear. Because
most patients with spasticity report pain independently
from the occurrence of exacerbations, pain probably
reflects the prolonged, abnormal muscle contraction. The
responsible mechanism differs from that for painful tonic
spasms, because the reflex motoneuronal activation pre-
vents simultaneous contraction of adjacent motor units, so
that ischemia is unlikely to develop. As happens when
untrained muscles undergo prolonged exercise, muscle
receptors are probably activated by the excessive muscular
work. This kind of muscle pain (mechanical muscle pain)
[63] is typical of eccentric contractions such as those in
spastic lower-limb extensors when the patient tries to flex
the knee during walking. Lengthening a contracted muscle
causes structural damage and disruption of even a few
muscle fibers releases abundant substances that may
directly or indirectly through biochemical changes excite
the muscle nociceptors [66]. Although some investigators
proposed that the usual algesic substances, such as brady-
kinin, serotonin, and prostaglandin E2, activate muscle
receptors in spasticity [115], mechanical muscle pain
seems not to respond to non-steroidal anti-inflammatory
drugs [63].
Although pain eventually arises from peripheral noci-
ceptors, evidence underlining that CNS has a primary role
comes from the response to treatment, showing that treat-
ments known to relieve spasticity also relieve spasticity-
related pain. Several controlled trials found that oral and
intrathecal baclofen effectively relieve spasticity and
spasticity-related pain [37, 61, 90], as does gabapentin [21,
65]. As expected, cannabinoids, substances that act both on
nociceptive and neuropathic pain, proved particularly
effective [116].
Nociceptive pains
Nerve trunk pain associated with optic neuritis
Optic neuritis is common in patients with MS. It is the
presenting manifestation in about 20 % of patients, and
often causes pain. Most studies assessing the prevalence of
pain in MS excluded optic neuritis from consideration [71],
owing to the lack of widely agreed diagnostic criteria [1].
The only study assessing the prevalence of pain in optic
neuritis found a value of 8 % [41]. Pain related to optic
neuritis presumably arises from the inflammation of the
optic nerve trunk (nerve trunk pain) that activates intra-
neural nociceptors innervated by nervi nervorum. The
possibility that inflammation directly (ectopically)
358 J Neurol (2013) 260:351–367
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activates the axons in the nervi nervorum seems unlikely,
given the dull character of pain.
Musculoskeletal pains secondary to postural anomalies
and low back pain
Patients with muscle weakness or spasticity are prone to
postural anomalies. Abnormal posture in turn perturbs
body weight distribution, entails excessive work for some
muscles, and induces excessive stress on ligaments and
joints. Even reduced mobility alone can lead to osteopo-
rosis, reduce elasticity in tendons and ligaments, and cause
joint ankylosis. Among other deleterious consequences, the
nociceptive input facilitates homotopical spinal vasocon-
strictor neurons, thus increasing pain [28, 50]. This vicious
circle must be counteracted from the very beginning, with
anti-inflammatory agents and most of all with intensive
postural physiotherapy. Our review found no studies esti-
mating the prevalence of musculoskeletal pains (other than
low back pain) in MS.
Multiple sclerosis particularly predisposes patients to
low back pain. Epidemiological studies reported a preva-
lence of low back pain in patients with MS ranging from 10
to 16 % [71, 97]. To what extent MS-dependent patho-
physiological mechanisms contribute to low back pain
remains unclear. Current evidence predominantly attributes
low back pain not to central inflammatory processes but to
the mechanisms we have already described for musculo-
skeletal pain in general [69]. Given the insufficient
understanding of the pain mechanisms associated with
mechanical back pain in general, it is virtually impossible
to estimate the importance of mechanisms directly related
to MS in patients complaining of low back pain.
Headache
All headaches, whether mediated by meningeal, arterial,
muscular, or other craniofacial tissue receptors, are noci-
ceptive pains. Whatever its nature, an association seems to
exist between headache and MS. Most studies agree that
the prevalence of headache is significantly higher in
patients with MS patients than in the general population
[71]. The reported frequencies vary widely, from 13 to
64 % [52, 71]. In their systematic review, O’Connor and
colleagues [71] found three studies specifically assessing
the prevalence of headache in MS: out of a total of 269
patients with MS, 86 had a primary form of headache
(51 %). Searching the literature published thereafter for
studies that focused on assessing the prevalence of head-
ache, provided separate data for migraine and tension-type
headache, and had a sample population of at least 100
patients, we found five articles [52, 68, 82, 109, 110]. Out
of a total of 1,136 MS patients, 669 had a primary headache
(59 %), i.e., a frequency similar to that reported in earlier
studies. Interestingly, 381 had migraine with or without
aura (34 %) and 242 had tension-type headache (21 %).
Whereas the frequency of migraine was significantly
higher in patients with MS than in healthy controls, that of
tension-type headache was not. Comparing the prevalence
of headache in MS with that in the general population in
Europe yields even more striking results. The prevalence of
migraine is three times higher in patients with MS than in
the general population, 34 versus 10 %, as estimated by the
European Brain Council [72], whereas the prevalence of
tension-type headache is similar, 21 versus 20–34 %, as
estimated by epidemiological studies in European Coun-
tries [58, 79, 82, 112]. Although some investigators refute
MS as a risk factor for headache, the high reported
migraine frequency in MS cannot be explained with a mere
coexistence of two diseases.
Either MS and migraine share some predisposing fac-
tor, or the MS lesions directly induce migraine pain.
Several reports have documented that migraine attacks
may manifest during symptom exacerbation and may even
herald the onset of relapse in MS [71]. Using MRI, a
study compared the frequency of lesions in the midbrain
(periaqueductal grey, substantia nigra, or red nucleus) in
58 patients with migraine (selected for having supraten-
torial infarctions), 42 patients with MS without migraine,
and 37 patients with MS and migraine: the frequency
increased from migraine (23 %), to MS without migraine
(32 %), to MS with migraine (52 %) [104]. In a survey of
277 MS patients, 95 having migraine (34 %), patients
with a plaque within the midbrain/periaqueductal grey
matter (an important area in the antinociceptive control
system) as demonstrated by MRI, had a four-fold higher
increase in migraine than those without a lesion in that
area [29]. Hence, demyelinating lesions in the midbrain,
and periaqueductal grey in particular, i.e., areas that are
supposedly involved in the pathophysiology of migraine
[114], are associated with the development of migraine in
MS.
Treatment-induced pains
Treatment for MS can also induce secondary nociceptive
pains [71]. Interferon beta induces a flu-like syndrome in
most patients with MS, some of whom report myalgias that
may persist for months. Again interferon beta (but not
glatiramer acetate or natalizumab) reportedly increases the
frequency and severity of headache. Pain at the injection
site for glatiramer acetate is a frequent complaint. Chronic
corticosteroid use can cause osteoporosis and secondary
pains [3, 71, 77, 80, 85, 111].
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Other types of pain
A number of other types of pain, although far less frequently,
have been reported. Central pains affecting the face or trunk,
rather than the extremities, resemble the ongoing extremity
pain and therefore probably arise through similar mecha-
nisms: when somatosensory testing discloses a deficit in
thermal-pain sensitivity in the same territory, pain should be
attributed to a lesion in the spinothalamic system. Other
types of pain include visceral pain and painful entrapment
neuropathies secondary to motor disorders; more research is
needed before drawing conclusions on both.
Conclusions
Patients with MS may present with a wide variety of symp-
toms. This multiform presentation holds true also for pain.
We can think of no other disease that can result in so many
different types of pain. This review emphasizes how
important it is to characterize the type of pain properly in
patients with MS. Many epidemiological studies and treat-
ment trials we reviewed reported poor outcomes precisely
because they neglected to categorize pain adequately. This
drawback impedes a mechanism-based approach.
This review nevertheless attempts a scheme of classifi-
cation. Admittedly, a great deal of the reasoning is spec-
ulative, again because we lack sufficient information on
specific types of pain. Future research needs to dig into the
mechanisms underlying the various MS-related pains so
that treatment can follow a mechanism-based approach.
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Appendix
Systematic search for randomized controlled trials (RCT)
assessing the efficacy of medical treatment of pain in
multiple sclerosis (MS).
Search strategy
We searched the PubMed expanded database from incep-
tion date to April 2012 using
• the search string: ‘‘multiple sclerosis AND (pain OR
painful OR analgesic OR antinociceptive)’’,
• the limits: ‘‘randomized controlled trial’’ AND ‘‘title/
abstract’’.
Inclusion criteria: placebo-controlled, double-blind
RCTs assessing the efficacy of pain-relieving (non disease-
modifying) drugs, in patients with multiple sclerosis.
Exclusion criteria: trials in multiple diseases without the
possibility of extrapolating the results relative to the
patients with multiple sclerosis, trials in less than ten
patients with MS, acute or short-lasting treatments.
This search yielded 62 articles. Because one was a
duplicate [1], we screened the abstract of 61 articles. Six-
teen articles were excluded after reading the abstract
because completely not pertinent [2–17]; 13 because
assessed non-pharmacological treatments [18–30], six
because assessed disease-modifying drugs [31–36], three
because assessed treatment-induced pain [37–39], one
because assessed experimental pain [40], five because of a
small sample size or because the trial assessed multiple
diseases without the possibility of extrapolating the results
in MS patients, [41–45] four because they were not double-
blind or were not placebo-controlled [46–49], and one
because the duration of treatment was only 2 days [50].
The remaining 12 studies were selected for analysis
[51–62] (see Prisma Chart and List of references).
PRISMA CHART
Records identified through database searching (n = 62) 
Duplicates (n = 1) 
Non pertinent (n = 16) 
Full-text articles 
assessed for eligibility
Full-text excluded  (n = 33) 
Non pharmacological studies (n = 13) 
Disease-modifying treatment (n = 6) 
Treatment-induced pain (n = 3) 
Experimental pain (n = 1) 
Insufficient sample (or multiple 
diseases with no specific information on 
MS patients) (n = 5) 
Insufficient control (single-blind or non-
placebo-controlled) (n = 4) 
Insufficient duration of treatment (n = 1) 
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